Cholangiocarcinoma — evolving concepts and therapeutic strategies

Ilyas, Sumera I.; Khan, Shahid A.; Hallemeier, Christopher L.; Kelley, Robin K.; Gores, Gregory J.

doi:10.1038/nrclinonc.2017.157

Cited by 1,626Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and TreatmentsLiver Diseases and Immunity

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Open access

Ilyas, Sumera I., Khan, Shahid A., Hallemeier, Christopher L., Kelley, Robin K., Gores, Gregory J.·2018·Nature Reviews Clinical Oncology

DOI 10.1038/nrclinonc.2017.157PMC PMC5819599

Open this paper in CoChat — free account

Abstract

Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features of cholangiocyte differentiation: cholangiocarcinomas are categorized according to anatomical location as intrahepatic (iCCA), perihilar (pCCA), or distal (dCCA). Each subtype has a distinct epidemiology, biology, prognosis, and strategy for clinical management. The incidence of cholangiocarcinoma, particularly iCCA, has increased globally over the past few decades. Surgical resection remains the mainstay of potentially curative treatment for all three disease subtypes, whereas liver transplantation after neoadjuvant chemoradiation is restricted to a subset of patients with early stage pCCA. For patients with advanced-stage or unresectable disease, locoregional and systemic chemotherapeutics are the primary treatment options. Improvements in external-beam radiation therapy have facilitated the treatment of cholangiocarcinoma. Moreover, advances in comprehensive whole-exome and transcriptome sequencing have defined the genetic landscape of each cholangiocarcinoma subtype. Accordingly, promising molecular targets for precision medicine have been identified, and are being evaluated in clinical trials, including those exploring immunotherapy. Biomarker-driven trials, in which patients are stratified according to anatomical cholangiocarcinoma subtype and genetic aberrations, will be essential in the development of targeted therapies. Targeting the rich tumour stroma of cholangiocarcinoma in conjunction with targeted therapies might also be useful. Herein, we review the evolving developments in the epidemiology, pathogenesis, and management of cholangiocarcinoma.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrclinonc.2017.157

Cites

175 of 175 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

An opposite, pro-oncogenic role for TBX3 has been revealed in other tumor types, such as malignant melanoma, breast, gastric, and cervical cancers.
“An opposite, pro-oncogenic role for TBX3 has been revealed in other tumor types, such as malignant melanoma, breast, gastric, and cervical cancers [1–3].”
From Overexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma (2024) · cites this paper as [1]
Our copy discusses genetic drivers and therapies for cholangiocarcinoma (Abstract, page unavailable), but the passages do not address a pro-oncogenic role for TBX3 in melanoma, breast, gastric, or cervical cancer. Searches for TBX3 and its expanded name with those cancer types found no relevant passage. (LLM, conf=0.76)
Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J. W., Wasan, H. S., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T. J., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,423 · see citing works
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286 · see citing works
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280 · see citing works
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,065 · see citing works
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · see citing works
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809 · see citing works
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502 · see citing works
Cholangiocarcinoma
Razumilava, N., & Gores, G. J. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61903-0 · Cited by 1,831 · see citing works
Self-citation
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · see citing works
Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma
Bridgewater, J. A., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J., Patel, T. C., Pawlik, T. M., & Gores, G. J. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.021 · Cited by 1,508 · see citing works
Self-citation
Staging, Resectability, and Outcome in 225 Patients With Hilar Cholangiocarcinoma
Jarnagin, W. R., Fong, Y., DeMatteo, R. P., Gönen, M., Burke, E. C., Bodniewicz, J., Youssef, M., Klimstra, D., & Blumgart, L. H. (2001) · Annals of Surgery · doi:10.1097/00000658-200110000-00010 · Cited by 1,342 · see citing works
Right Portal Vein Ligation Combined With In Situ Splitting Induces Rapid Left Lateral Liver Lobe Hypertrophy Enabling 2-Staged Extended Right Hepatic Resection in Small-for-Size Settings
Schnitzbauer, A. A., Lang, S. A., Goessmann, H., Nadalin, S., Baumgart, J., Farkas, S. A., Fichtner‐Feigl, S., Lorf, T., Goralcyk, A., Hörbelt, R., et al. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e31824856f5 · Cited by 1,330 · see citing works
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,311 · see citing works
Self-citation
Cholangiocarcinoma
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,301 · see citing works
Genomic spectra of biliary tract cancer
Nakamura, H. K., Arai, Y., Totoki, Y., Shirota, T., Elzawahry, A., Kato, M., Hama, N., Hosoda, F., Urushidate, T., Ohashi, S., et al. (2015) · Nature Genetics · doi:10.1038/ng.3375 · Cited by 1,288 · see citing works
Cholangiocarcinoma
Nakeeb, A., Pitt, H. A., Riall, T. S., Coleman, J., Abrams, R. A., Piantadosi, S., Hruban, R. H., Lillemoe, K. D., Yeo, C. J., & Cameron, J. L. (1996) · Annals of Surgery · doi:10.1097/00000658-199610000-00005 · Cited by 1,207 · see citing works
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells
Rohle, D., Popovici-Muller, J., Palaskas, N., Turcan, S., Grommes, C., Campos, C., Tsoi, J., Clark, O., Oldrini, B., Komisopoulou, E., et al. (2013) · Science · doi:10.1126/science.1236062 · Cited by 1,153 · see citing works
The Epidemiology of Cholangiocarcinoma
Shaib, Y. H., & El‐Serag, H. B. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,134 · see citing works
Intrahepatic Cholangiocarcinoma
Endo, I., Gönen, M., Yopp, A. C., Dalal, K. M., Zhou, Q. C., Klimstra, D. S., D'Angelica, M. I., DeMatteo, R. P., Fong, Y., Schwartz, L. H., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176c4d3 · Cited by 867 · see citing works
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation
Wang, F., Travins, J., DeLaBarre, B., Penard-Lacronique, V., Schalm, S., Hansen, E., Straley, K., Kernytsky, A., Liu, W., Gliser, C., et al. (2013) · Science · doi:10.1126/science.1234769 · Cited by 804 · see citing works
Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: Intrahepatic Disease on the Rise
Saha, S. K., Zhu, A. X., Fuchs, C. S., & Brooks, G. A. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0446 · Cited by 787 · see citing works
Radiation-Associated Liver Injury
Pan, C. C., Kavanagh, B. D., Dawson, L. A., Li, X. A., Das, S. K., Miften, M. M., & Haken, R. K. T. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.092 · Cited by 755 · see citing works
Identification of Targetable FGFR Gene Fusions in Diverse Cancers
Wu, Y.-M., Su, F., Sundaram, S. K., Khazanov, N. A., Ateeq, B., Cao, X., Lonigro, R. J., Vats, P., Wang, R., Lin, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0050 · Cited by 748 · see citing works
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
Okusaka, T., Nakachi, K., Fukutomi, A., Mizuno, N., Ohkawa, S., Funakoshi, A., Nagino, M., Kondo, S., Nagaoka, S., Funai, J., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605779 · Cited by 745 · see citing works
Frequent Mutation of Isocitrate Dehydrogenase(IDH)1andIDH2in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping
Borger, D. R., Tanabe, K. K., Fan, K. C., Lopez, H. U., Fantin, V. R., Straley, K. S., Schenkein, D. P., Hezel, A. F., Ancukiewicz, M., Liebman, H. M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0386 · Cited by 728 · see citing works
Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis
Horgan, A. M., Amir, E., Walter, T., & Knox, J. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5381 · Cited by 714 · see citing works
Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas
Jiao, Y., Pawlik, T. M., Anders, R. A., Selaru, F. M., Streppel, M. M., Lucas, D. J., Niknafs, N., Guthrie, V. B., Maitra, A., Argani, P., et al. (2013) · Nature Genetics · doi:10.1038/ng.2813 · Cited by 689 · see citing works
Self-citation
Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
Shaib, Y. H., Davila, J. A., McGlynn, K. A., & El‐Serag, H. B. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.030 · Cited by 682 · see citing works
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Farshidfar, F., Zheng, S., Gingras, M., Newton, Y., Shih, J., Robertson, A. G., Hinoue, T., Hoadley, K. A., Gibb, E. A., Roszik, J., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.033 · Cited by 611 · see citing works
Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers
Darwish Murad, S., Kim, W. R., Harnois, D. M., Douglas, D. D., Burton, J., Kulik, L. M., Botha, J. F., Mezrich, J. D., Chapman, W. C., Schwartz, J. J., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.008 · Cited by 597 · see citing works
Self-citation
Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Tse, R. V., Hawkins, M., Lockwood, G. A., Kim, J. J., Cummings, B., Knox, J. J., Sherman, M., & Dawson, L. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3529 · Cited by 590 · see citing works
Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes
Sia, D., Hoshida, Y., Villanueva, A., Roayaie, S., Ferrer, J., Tabak, B., Peix, J., Solé, M., Tovar, V., Alsinet, C., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.001 · Cited by 575 · see citing works
Changing international trends in mortality rates for liver, biliary and pancreatic tumours
Khan, S. A., Taylor-Robinson, S. D., Toledano, M. B., Beck, A. J., Elliott, P., & Thomas, H. C. (2002) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00297-0 · Cited by 571 · see citing works
Self-citation
Radiation Dose–Volume Effects in the Stomach and Small Bowel
Kavanagh, B. D., Pan, C. C., Dawson, L. A., Das, S. K., Li, X. A., Haken, R. K. T., & Miften, M. M. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.05.071 · Cited by 549 · see citing works
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma
Palmer, W. C., & Patel, T. C. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.02.022 · Cited by 532 · see citing works
Cholangiocarcinoma: lessons from Thailand
Sripa, B., & Pairojkul, C. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbf9b3 · Cited by 532 · see citing works
Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers
Chan-on, W., Nairismägi, M., Ong, C. K., Lim, W. K., Dima, S., Pairojkul, C., Lim, K. H., McPherson, J. R., Cutcutache, I., Heng, H. L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2806 · Cited by 495 · see citing works
Worldwide trends in mortality from biliary tract malignancies
Patel, T. C. (2002) · BMC Cancer · doi:10.1186/1471-2407-2-10 · Cited by 491 · see citing works
Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma
Hong, T. S., Wo, J. Y.-L., Yeap, B. Y., Ben‐Josef, E., McDonnell, E., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Clark, J. W., Goyal, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2710 · Cited by 474 · see citing works
New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing
Ross, J. S., Wang, K., Gay, L. M., Al-Rohil, R. N., Rand, J. V., Jones, D., Lee, H. J., Sheehan, C. E., Otto, G. A., Palmer, G. A., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0352 · Cited by 453 · see citing works
Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R. T., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D. S., Meric‐Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450 · see citing works
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
Carbognin, L., Pilotto, S., Milella, M., Vaccaro, V., Brunelli, M., Caliò, A., Cuppone, F., Sperduti, I., Giannarelli, D., Chilosi, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130142 · Cited by 450 · see citing works
The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis
Patel, A. H., Harnois, D. M., Klee, G. G., LaRusso, N. F., & Gores, G. J. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01685.x · Cited by 424 · see citing works
Self-citation
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Ben‐Josef, E., Guthrie, K. A., El-Khoueiry, A. B., Corless, C. L., Zalupski, M. M., Lowy, A. M., Thomas, C. R., Alberts, S. R., Dawson, L. A., Micetich, K. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.2219 · Cited by 420 · see citing works
Hilar cholangiocarcinoma: expert consensus statement
Mansour, J. C., Aloia, T. A., Crane, C. H., Heimbach, J. K., Nagino, M., & Vauthey, J.-N. (2015) · HPB · doi:10.1111/hpb.12450 · Cited by 414 · see citing works
SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
Kim, K. H., Kim, W., Howard, T. P., Vázquez, F., Tsherniak, A., Wu, J. N., Wang, W., Haswell, J. R., Walensky, L. D., Hahn, W. C., et al. (2015) · Nature Medicine · doi:10.1038/nm.3968 · Cited by 407 · see citing works
Epidemiology of cholangiocarcinoma
Bergquist, A. M., & von Seth, E. (2015) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2015.02.003 · Cited by 400 · see citing works
Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis
Charatcharoenwitthaya, P., Enders, F. B., Halling, K. C., & Lindor, K. D. (2008) · Hepatology · doi:10.1002/hep.22441 · Cited by 393 · see citing works
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
Valle, J. W., Furuse, J., Jitlal, M., Beare, S., Mizuno, N., Wasan, H. S., Bridgewater, J. A., & Okusaka, T. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt540 · Cited by 391 · see citing works
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Tabernero, J. M., Bahleda, R., Dienstmann, R., Infante, J. R., Mita, A. C., Italiano, A., Calvo, E., Moreno, V., Adamo, B., Gazzah, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.7341 · Cited by 390 · see citing works
Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998
Taylor-Robinson, S. D., Toledano, M. B., Arora, S., Keegan, T., Hargreaves, S., Beck, A. J., Khan, S. A., Elliott, P., & Thomas, H. C. (2001) · Gut · doi:10.1136/gut.48.6.816 · Cited by 380 · see citing works
Self-citation
Liver transplantation for “very early” intrahepatic cholangiocarcinoma: International retrospective study supporting a prospective assessment
Sapisochín, G., Facciuto, M. E., Rubbia‐Brandt, L., Martí, J. M., Mehta, N. J., Yao, F. Y., Vibert, É., Cherqui, D., Grant, D. R., Hernandez‐Alejandro, R., et al. (2016) · Hepatology · doi:10.1002/hep.28744 · Cited by 369 · see citing works
Molecular Gene Expression Profiling to Predict the Tissue of Origin and Direct Site-Specific Therapy in Patients With Carcinoma of Unknown Primary Site: A Prospective Trial of the Sarah Cannon Research Institute
Hainsworth, J. D., Rubin, M. S., Spigel, D. R., Boccia, R. V., Raby, S., Quinn, R., & Greco, F. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3755 · Cited by 365 · see citing works
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
Amatangelo, M. D., Quek, L. S., Shih, A. H., Stein, E. M., Roshal, M., David, M. D., Marteyn, B., Farnoud, N. R., de Botton, S., Bernard, O., et al. (2017) · Blood · doi:10.1182/blood-2017-04-779447 · Cited by 358 · see citing works
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Perera, T. P. S., Jovcheva, E., Mévellec, L., Vialard, J. E., Lange, D. D., Verhulst, T., Paulussen, C., Ven, K. V. D., King, P., Freyne, E. J. E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0589 · Cited by 346 · see citing works
Integrated Genomic Characterization Reveals Novel, Therapeutically Relevant Drug Targets in FGFR and EGFR Pathways in Sporadic Intrahepatic Cholangiocarcinoma
Borad, M. J., Champion, M. D., Egan, J. B., Liang, W. S., Fonseca, R., Bryce, A. H., McCullough, A. E., Barrett, M. T., Hunt, K. S., Patel, M. D., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004135 · Cited by 341 · see citing works
The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339 · see citing works
Self-citation
Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma
Sia, D., Losic, B., Moeini, A., Cabellos, L., Hao, K., Revill, K., Bonal, D. M., Miltiadous, O., Zhang, Z., Hoshida, Y., et al. (2015) · Nature Communications · doi:10.1038/ncomms7087 · Cited by 312 · see citing works
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis
Tao, R., Krishnan, S., Bhosale, P., Javle, M. M., Aloia, T. A., Shroff, R. T., Kaseb, A. O., Bishop, A. J., Swanick, C. W., Koay, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.3778 · Cited by 310 · see citing works
Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human Cholangiocarcinoma
Gu, T.-L., Deng, X., Huang, F., Tucker, M., Crosby, K., Rimkunas, V. M., Wang, Y., Deng, G., Zhu, L., Tan, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015640 · Cited by 307 · see citing works
The Prognosis and Survival Outcome of Intrahepatic Cholangiocarcinoma Following Surgical Resection: Association of Lymph Node Metastasis and Lymph Node Dissection with Survival
Choi, S.-B., Kim, K. S., Choi, J., Park, S. W., Choi, J.-S., Lee, W. J., & Chung, J.-B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0631-1 · Cited by 304 · see citing works
Spanish Experience in Liver Transplantation for Hilar and Peripheral Cholangiocarcinoma
Robles-Campos, R., Figueras, J., Turrión, V. S., Margarit, C., Moya, A., Varó, E., Calleja, J., Valdivieso, A., Valdecasas, J. C. G., López, P., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000108702.45715.81 · Cited by 303 · see citing works
Multi-Institutional Phase II Study of Selumetinib in Patients With Metastatic Biliary Cancers
Bekaii‐Saab, T., Phelps, M. A., Li, X., Saji, M., Goff, L. W., Kauh, J. S. W., O’Neil, B. H., Balsom, S., Balint, C. R., Liersemann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.9473 · Cited by 303 · see citing works
Cholangiocarcinoma in cirrhosis: Absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma # †
Rimola, J., Forner, A., Reig, M., Vilana, R., de Lope, C. R., Ayuso, C., & Bruix, J. (2009) · Hepatology · doi:10.1002/hep.23071 · Cited by 297 · see citing works
Rising trends in cholangiocarcinoma: Is the ICD classification system misleading us?
Khan, S. A., Emadossadaty, S., Ladep, N. G., Thomas, H. C., Elliott, P., Taylor-Robinson, S. D., & Toledano, M. B. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.11.015 · Cited by 290 · see citing works
Self-citation
Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma
Arbelaiz, A., Azkargorta, M., Krawczyk, M. J., Santos‐Laso, Á., Lapitz, A., Perugorria, M. J., Erice, O., González, E., Jiménez-Agüero, R., Casta, A. L., et al. (2017) · Hepatology · doi:10.1002/hep.29291 · Cited by 289 · see citing works
Self-citation
Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma.
Graham, R. P., Fritcher, E. B. B., Pestova, E., Schulz, J., Sitailo, L., Vasmatzis, G., Murphy, S., McWilliams, R., Hart, S., Halling, K., et al. (2014) · Human Pathology · doi:10.1016/j.humpath.2014.03.014 · Cited by 289 · see citing works
Self-citation
Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination
Heimbach, J. K., Sánchez, W., Rosen, C. B. B., & Gores, G. J. (2011) · HPB · doi:10.1111/j.1477-2574.2011.00298.x · Cited by 287 · see citing works
Self-citation
Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma
Horlad, H., Komohara, Y., Okabe, H., Masuda, T., Ohnishi, K., Lei, X., Beppu, T., Baba, H., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01614.x · Cited by 274 · see citing works
Liver transplantation for cholangiocarcinoma
Rosen, C. B., Heimbach, J. K., & Gores, G. J. (2010) · Transplant International · doi:10.1111/j.1432-2277.2010.01108.x · Cited by 271 · see citing works
Self-citation
Cancer of Unknown Primary Site
Varadhachary, G. R., & Raber, M. N. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1303917 · Cited by 267 · see citing works
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma
Kipp, B. R., Voss, J. S., Kerr, S. E., Fritcher, E. G. B., Graham, R. P., Zhang, L., Highsmith, W. E., Zhang, J., Roberts, L. R., Gores, G. J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.12.007 · Cited by 243 · see citing works
Self-citation
Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience
Mohamadnejad, M., DeWitt, J. M., Sherman, S., LeBlanc, J. K., Pitt, H. A., House, M. G., Jones, K. J., Fogel, E. L., McHenry, L., Watkins, J. L., et al. (2010) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2010.08.050 · Cited by 239 · see citing works
Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001
West, J., WOOD, H. E., Logan, R. F., Quinn, M. J., & Aithal, G. P. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603127 · Cited by 234 · see citing works
Human bile contains MicroRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis
Li, L., Masica, D. L., Ishida, M., Tomuleasa, C., Umegaki, S., Kalloo, A. N., Georgiades, C. S., Singh, V. K., Khashab, M. A., Amateau, S. K., et al. (2014) · Hepatology · doi:10.1002/hep.27050 · Cited by 224 · see citing works
Transarterial Hepatic Yttrium-90 Radioembolization in Patients with Unresectable Intrahepatic Cholangiocarcinoma: Factors Associated with Prolonged Survival
Hoffmann, R., Paprottka, P. M., Schön, A., Bamberg, F., Haug, A. R., Dürr, E.-M., Rauch, B., Trumm, C., Jakobs, T. F., Helmberger, T. K., et al. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0142-x · Cited by 223 · see citing works
Whole-genome mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis impact and molecular diversity
Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K., Nakamura, T., Ueno, M., Ariizumi, S.-I., Hà, N. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms7120 · Cited by 223 · see citing works
Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma
Mertens, J. C., Fingas, C. D., Christensen, J. D., Smoot, R. L., Bronk, S. F., Werneburg, N. W., Gustafson, M. P., Dietz, A. B., Roberts, L. R., Sirica, A. E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2130 · Cited by 212 · see citing works
Self-citation
Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta-analysis
Trikudanathan, G., Navaneethan, U., Njei, B., Vargo, J. J., & Parsi, M. A. (2014) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2013.09.015 · Cited by 203 · see citing works
“Very Early” Intrahepatic Cholangiocarcinoma in Cirrhotic Patients: Should Liver Transplantation Be Reconsidered in These Patients?
Sapisochín, G., de Lope, C. R., Gastaca, M., de Urbina, J. O., Suárez, M. A., Santoyo, J. S., Castroagudı́n, J. F., Varó, E., López‐Andújar, R., Palacios, F., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12591 · Cited by 198 · see citing works
PD-L1 Expression as a Predictive Biomarker in Advanced Non-Small-Cell Lung Cancer: Updated Survival Data
Aguiar, P. N., de Mello, R. A., Hall, P. S., Tadokoro, H., & Lopes, G. D. L., Jr. (2017) · Immunotherapy · doi:10.2217/imt-2016-0150 · Cited by 196 · see citing works
Adjuvant capecitabine for biliary tract cancer: The BILCAP randomized study.
Primrose, J. M., Fox, R., Palmer, D. H., Prasad, R. K., Mirza, D. F., Anthoney, D. A., Corrie, P., Falk, S. J., Wasan, H. S., Ross, P. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.4006 · Cited by 190 · see citing works
Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma
Yachida, S., Wood, L. D., Suzuki, M., Takai, E., Totoki, Y., Kato, M., Luchini, C., Arai, Y., Nakamura, H. K., Hama, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.012 · Cited by 186 · see citing works
Serum and Bile Markers for Cholangiocarcinoma
Nehls, O., Gregor, M., & Klump, B. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828891 · Cited by 181 · see citing works
PD-L1 expression in perihilar and intrahepatic cholangiocarcinoma
Fontugne, J., Augustin, J., Pujals, A., Compagnon, P., Rousseau, B., Luciani, A., Tournigand, C., Cherqui, D., Azoulay, D., Pawlotsky, J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15602 · Cited by 179 · see citing works
Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis
Ruys, A. T., Beem, B. E. V., Engelbrecht, M. R. W., Bipat, S., Stoker, J., & van Gulik, T. M. (2012) · British Journal of Radiology · doi:10.1259/bjr/88405305 · Cited by 175 · see citing works
External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma
Foo, M. L., Gunderson, L. L., Bender, C. E., & Buskirk, S. J. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00299-x · Cited by 175 · see citing works
Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency
Silva, V. W. K., Askan, G., Daniel, T. D., Lowery, M. A., Klimstra, D. S., Abou‐Alfa, G. K., & Shia, J. (2016) · Chinese Clinical Oncology · doi:10.21037/cco.2016.10.04 · Cited by 169 · see citing works
Bile Proteomic Profiles Differentiate Cholangiocarcinoma From Primary Sclerosing Cholangitis and Choledocholithiasis §Δ
Lankisch, T. O., Metzger, J., Negm, A. A., Voβkuhl, K., Schiffer, E., Siwy, J., Weismüller, T. J., Schneider, A. S., Thedieck, K., Baumeister, R., et al. (2010) · Hepatology · doi:10.1002/hep.24103 · Cited by 162 · see citing works
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol
Kiefer, M. V., Albert, M., McNally, M., Robertson, M. C., Sun, W., Fraker, D. L., Olthoff, K. M., Christians, K. K., Pappas, S. G., Rilling, W. S., et al. (2010) · Cancer · doi:10.1002/cncr.25625 · Cited by 161 · see citing works
Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Saha, S. K., Gordan, J. D., Kleinstiver, B. P., Vu, P., Najem, M. S., Yeo, J.-C., Shi, L., Kato, Y., Levin, R. S., Webber, J. T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1442 · Cited by 160 · see citing works
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Gani, F., Nagarajan, N., Kim, Y., Zhu, Q., Luan, L., Bhaijee, F., Anders, R. A., & Pawlik, T. M. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5101-y · Cited by 155 · see citing works
Yttrium-90 Radioembolization for Unresectable Standard-chemorefractory Intrahepatic Cholangiocarcinoma: Survival, Efficacy, and Safety Study
Rafi, S., Piduru, S. M., El‐Rayes, B. F., Kauh, J. S. W., Kooby, D. A., Sarmiento, J. M., & Kim, H. S. (2012) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-012-0463-4 · Cited by 155 · see citing works
Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma
Park, S.-Y., Kim, J. H., Yoon, H.-J., Lee, I., Yoon, H., & Kim, K.-P. (2011) · Clinical Radiology · doi:10.1016/j.crad.2010.11.002 · Cited by 152 · see citing works
Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets
Zhu, A. X., Borger, D. R., Kim, Y., Cosgrove, D. C., Ejaz, A. M., Alexandrescu, S. T., Groeschl, R. T., Deshpande, V., Lindberg, J. M., Ferrone, C. R., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3828-x · Cited by 150 · see citing works
Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation
Gingras, M., Covington, K. R., Chang, D. K.-F., Donehower, L. A., Gill, A. J., Ittmann, M., Creighton, C. J., Johns, A. L., Shinbrot, E., Dewal, N., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.005 · Cited by 149 · see citing works
An Optimized Set of Fluorescence In Situ Hybridization Probes for Detection of Pancreatobiliary Tract Cancer in Cytology Brush Samples
Fritcher, E. G. B., Voss, J. S., Brankley, S. M., Campion, M. B., Jenkins, S. M., Keeney, M. E., Henry, M. R., Kerr, S., Chaiteerakij, R., Pestova, E. V., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.046 · Cited by 148 · see citing works
Self-citation
525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: Interim results of KEYNOTE-028
Bang, Y., Doi, T., de Braud, F., Piha-Paul, S. A., Hollebecque, A., Razak, A. R. A., Lin, C., Ott, P., He, A. R., Yuan, S., et al. (2015) · European Journal of Cancer · doi:10.1016/s0959-8049(16)30326-4 · Cited by 145 · see citing works
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success
Vogl, T. J., Naguib, N. N. N., Nour-Eldin, N.-E. A., Bechstein, W. O., Zeuzem, S., Trojan, J., & Gruber‐Rouh, T. (2011) · International Journal of Cancer · doi:10.1002/ijc.26407 · Cited by 144 · see citing works
Immunotherapy against cancer-related viruses
Tashiro, H., & Brenner, M. K. (2016) · Cell Research · doi:10.1038/cr.2016.153 · Cited by 143 · see citing works
Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders
Metzger, J., Negm, A. A., Plentz, R. R., Weismüller, T. J., Wedemeyer, J., Karlsen, T. H., Dakna, M., Mullen, W., Mischak, H., Manns, M. P., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302047 · Cited by 137 · see citing works
A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe
Bertuccio, P., Bosetti, C., Levi, F., Decarli, A., Negri, E., & Vecchia, C. L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds652 · Cited by 135 · see citing works
BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma
Goeppert, B. F., Frauenschuh, L., Renner, M., Roessler, S. K., Stenzinger, A., Klauschen, F., Warth, A., Vogel, M. N., Mehrabi, A., Hafezi, M., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.206 · Cited by 133 · see citing works
Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
Golan, T., Raitses‐Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0415 · Cited by 128 · see citing works
Self-citation
Clinical Features, Response to Treatment, and Outcomes of IgG4-Related Sclerosing Cholangitis
Tanaka, A., Tazuma, S., Okazaki, K., Nakazawa, T., Inui, K., Chiba, T., & Takikawa, H. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.12.038 · Cited by 125 · see citing works
Contrast enhanced CT-scan to diagnose intrahepatic cholangiocarcinoma in patients with cirrhosis
Iavarone, M. A., Piscaglia, F., Vavassori, S., Galassi, M., Sangiovanni, A., Venerandi, L., Forzenigo, L. V., Golfieri, R., Bolondi, L., & Colombo, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.013 · Cited by 124 · see citing works
The expanding role of immunotherapy
Martín-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J. A., & Tabernero, J. M. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.01.008 · Cited by 123 · see citing works
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
El-Khoueiry, A. B., Rankin, C. J., Siegel, A. B., Iqbal, S., Gong, I.-Y., Micetich, K. C., Kayaleh, O. R., Lenz, H. J., & Blanke, C. D. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.801 · Cited by 122 · see citing works
Treatment of unresectable cholangiocarcinoma
Kuhlmann, J. B., Euringer, W., Spangenberg, H. C., Breidert, M., Blum, H. E., Harder, J., & Fischer, R. (2012) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283502241 · Cited by 122 · see citing works
A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma
Goyal, L., Zheng, H., Yurgelun, M. B. B., Abrams, T. A., Allen, J. N., Cleary, J. M., Knowles, M., Regan, E. M., Reardon, A., Khachatryan, A., et al. (2017) · Cancer · doi:10.1002/cncr.30571 · Cited by 121 · see citing works
Salvage parenchymal liver transection for patients with insufficient volume increase after portal vein occlusion – An extension of the ALPPS approach
Tschuor, C., Croome, K. P., Sergeant, G., Cano, V., Schadde, E., Ardiles, V., Slankamenac, K., Clariá, R. S., de Santibáñes, E., Hernandez‐Alejandro, R., et al. (2013) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2013.08.009 · Cited by 118 · see citing works
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
Andresen, K., Boberg, K. M., Vedeld, H. M., Honne, H., Jebsen, P., Hektoen, M., Wadsworth, C. A., Clausen, O. P. F., Lundin, K. E. A., Paulsen, V., et al. (2015) · Hepatology · doi:10.1002/hep.27707 · Cited by 115 · see citing works
Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.
Edeline, J., Bonnetain, F., Phelip, J., Watelet, J., Hammel, P. R., Joly, J., Abdelghani, M. B., Rosmorduc, O., Bouhier‐Leporrier, K., Jouve, J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.4_suppl.225 · Cited by 110 · see citing works
Next-Generation Sequencing and Fluorescence in Situ Hybridization Have Comparable Performance Characteristics in the Analysis of Pancreaticobiliary Brushings for Malignancy
Dudley, J. C., Zheng, Z., McDonald, T. O., Le, L. P., Dias-Santagata, D. C., Borger, D. R., Batten, J. M., Vernovsky, K., Sweeney, B. J., Arpin, R., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.08.002 · Cited by 109 · see citing works
Solutions that enable ablative radiotherapy for large liver tumors: Fractionated dose painting, simultaneous integrated protection, motion management, and computed tomography image guidance
Crane, C. H., & Koay, E. J. (2016) · Cancer · doi:10.1002/cncr.29878 · Cited by 108 · see citing works
MR imaging and MR cholangiopancreatography in the preoperative evaluation of hilar cholangiocarcinoma: correlation with surgical and pathologic findings
Masselli, G., Manfredi, R. M., Vecchioli, A., & Gualdi, G. (2008) · European Radiology · doi:10.1007/s00330-008-1004-z · Cited by 107 · see citing works
Extracellular Vesicles in Bile as Markers of Malignant Biliary Stenoses
Severino, V., Dumonceau, J., Delhaye, M., Moll, S., Annessi-Ramseyer, I., Robin, X., Frossard, J., & Farina, A. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.04.043 · Cited by 102 · see citing works
Staging cholangiocarcinoma by imaging studies
Vilgrain, V. (2008) · HPB · doi:10.1080/13651820801992617 · Cited by 98 · see citing works
Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors
Feldman, S. A., Assadipour, Y., Kriley, I. R., Goff, S. L., & Rosenberg, S. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.005 · Cited by 96 · see citing works
Tumor reactive stroma in cholangiocarcinoma: The fuel behind cancer aggressiveness
Brivio, S., Cadamuro, M., Strazzabosco, M., & Fabris, L. (2017) · World Journal of Hepatology · doi:10.4254/wjh.v9.i9.455 · Cited by 96 · see citing works
A Hippo and Fibroblast Growth Factor Receptor Autocrine Pathway in Cholangiocarcinoma
Ilyas, S. I., Yamada, D., Hirsova, P., Bronk, S. F., Werneburg, N. W., Krishnan, A., Salim, W., Zhang, L. N., Trushina, E. V., Truty, M. J., et al. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.698472 · Cited by 94 · see citing works
Self-citation
Incidence Rates of Intra- and Extrahepatic Cholangiocarcinomas in Denmark From 1978 Through 2002
Jepsen, P., Vilstrup, H., Tarone, R. E., Friis, S., & Sørensen, H. T. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk201 · Cited by 91 · see citing works
Descriptive epidemiology of cholangiocarcinoma in Italy
Alvaro, D., Crocetti, E., Ferretti, S., Bragazzi, M. C., & Capocaccia, R. (2009) · Digestive and Liver Disease · doi:10.1016/j.dld.2009.10.009 · Cited by 88 · see citing works
Impact of microenvironment and stem-like plasticity in cholangiocarcinoma: Molecular networks and biological concepts
Raggi, C., Invernizzi, P., & Andersen, J. B. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.007 · Cited by 87 · see citing works
Portal Vein Resection in Management of Hilar Cholangiocarcinoma
Hemming, A. W., Mekeel, K. L., Khanna, A., Baquerizo, A., & Kim, R. D. (2011) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2010.12.028 · Cited by 87 · see citing works
Radiotherapy Is Associated With Improved Survival in Adjuvant and Palliative Treatment of Extrahepatic Cholangiocarcinomas
Shinohara, E. T., Mitra, N., Guo, M., & Metz, J. M. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.09.017 · Cited by 86 · see citing works
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors
Pant, S., Saleh, M. N., Bendell, J. C., Infante, J. R., Jones, S. F., Kurkjian, C. D., Moore, K. N., Kazakin, J., Abbadessa, G., Wang, Y., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu157 · Cited by 84 · see citing works
Geographic Variation of Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma, and Hepatocellular Carcinoma in the United States
Altekruse, S. F., Petrick, J. L., Rolin, A. I., Cucinelli, J. E., Zou, Z., Tatalovich, Z., & McGlynn, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0120574 · Cited by 79 · see citing works
Typical and Atypical Imaging Findings of Intrahepatic Cholangiocarcinoma Using Gadolinium Ethoxybenzyl Diethylenetriamine Pentaacetic Acid–Enhanced Magnetic Resonance Imaging
Kim, S., Lee, C. H., Kim, B. H., Kim, W. B., Yeom, S. K., Kim, K. A., & Park, C. M. (2012) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0b013e3182706562 · Cited by 79 · see citing works
Trends in the incidence and management of biliary tract cancer: A French population-based study
Lepage, C., Cottet, V., Chauvenet, M., Phelip, J., Bedenne, L., Faivre, J., & Bouvier, A. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.06.039 · Cited by 79 · see citing works
FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism
Acquaviva, J., He, S., Zhang, C., Jimenez, J.-P., Nagai, M., Sang, J., Sequeira, M., Smith, D. L., Ogawa, L. S., Inoue, T., et al. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0004 · Cited by 75 · see citing works
Mouse model of intrahepatic cholangiocarcinoma validates FIG–ROS as a potent fusion oncogene and therapeutic target
Saborowski, A. L., Saborowski, M., Davare, M. A., Druker, B. J., Klimstra, D. S., & Lowe, S. W. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311707110 · Cited by 73 · see citing works
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study
Bridgewater, J. A., Lopes, A., Beare, S., Duggan, M., Lee, D., Ricamara, M., McEntee, D., Sukumaran, A., Wasan, H. S., & Valle, J. W. (2016) · BMC Cancer · doi:10.1186/s12885-016-2174-8 · Cited by 72 · see citing works
Radiotherapy in the Treatment of Patients With Unresectable Extrahepatic Cholangiocarcinoma
Ghafoori, A. P., Nelson, J. W., Willett, C. G., Chino, J., Tyler, D. S., Hurwitz, H. I., Uronis, H. E., Morse, M. A., Clough, R. W., & Czito, B. G. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.06.018 · Cited by 67 · see citing works
Intrahepatic cholangiocarcinoma: indication for transplantation
Pascher, A., Jonas, S., & Neuhaus, P. (2003) · Journal of Hepato-Biliary-Pancreatic Surgery · doi:10.1007/s00534-002-0731-9 · Cited by 66 · see citing works
Enhancer of Zeste Homolog 2 (EZH2) Promotes Progression of Cholangiocarcinoma Cells by Regulating Cell Cycle and Apoptosis
Nakagawa, S., Okabe, H., Sakamoto, Y., Hayashi, H., Hashimoto, D., Yokoyama, N., Sakamoto, K., Kuroki, H., Mima, K., Nitta, H., et al. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3135-y · Cited by 66 · see citing works
Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment
Li, Y., Li, H., Lv, P., Liu, G., Li, X., Tian, B., & Chen, D. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1419-8 · Cited by 66 · see citing works
Cholangiocarcinoma: increasing burden of classifications.
Cardinale, V., Bragazzi, M. C., Carpino, G., Torrice, A., Fraveto, A., Gentile, R., Pasqualino, V., Melandro, F., Aliberti, C., Bastianelli, C., et al. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2304-3881.2013.10.02 · Cited by 62 · see citing works
Hepatic Resection in the Treatment of Hilar Cholangiocarcinoma
Nagorney, D. M., & Kendrick, M. L. (2006) · Advances in Surgery · doi:10.1016/j.yasu.2006.05.009 · Cited by 61 · see citing works
Intracellular localization of mesothelin predicts patient prognosis of extrahepatic bile duct cancer
Kawamata, F., Kamachi, H., Einama, T., Homma, S., Tahara, M., MIYAZAKI, M., Tanaka, S., Kamiyama, T., Nishihara, H., Taketomi, A., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1662 · Cited by 61 · see citing works
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells
Baradari, V. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i33.4458 · Cited by 58 · see citing works
Platelet-derived Growth Factor Primes Cancer-associated Fibroblasts for Apoptosis
Ilyas, S. I., Mertens, J. C., Bronk, S. F., Hirsova, P., Dai, H., Roberts, L. R., Kaufmann, S. H., & Gores, G. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.563064 · Cited by 56 · see citing works
Self-citation
A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.
Javle, M. M., Shroff, R. T., Zhu, A. X., Sadeghi, S., Choo, S., Borad, M. J., Lowery, M. A., El-Khoueiry, A. B., Macarulla, T. M., Philip, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.4_suppl.335 · Cited by 55 · see citing works
The underreporting of hepatocellular carcinoma to the cancer register and a log‐linear model to estimate a more correct incidence
Törner, A., Stokkeland, K., Svensson, Å., Dickman, P. W., Hultcrantz, R. W., Montgomery, S., & Duberg, A. (2016) · Hepatology · doi:10.1002/hep.28775 · Cited by 49 · see citing works
Mutation Profile and Fluorescence In Situ Hybridization Analyses Increase Detection of Malignancies in Biliary Strictures
Gonda, T. A., Viterbo, D., Gausman, V., Kipp, C., Sethi, A., Poneros, J. M., Gress, F. G., Park, T., Khan, A., Jackson, S. A., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.12.013 · Cited by 49 · see citing works
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells
Nakagawa, S., Sakamoto, Y., OKABE, H., Hayashi, H., Hashimoto, D., Yokoyama, N., Tokunaga, R., Sakamoto, K., Kuroki, H., Mima, K., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2922 · Cited by 48 · see citing works
Epigenome dysregulation in cholangiocarcinoma
O’Rourke, C. J., Muñoz-Garrido, P., Aguayo, E. L., & Andersen, J. B. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.014 · Cited by 48 · see citing works
Immune Checkpoint Inhibitors in Malignancies with Mismatch Repair Deficiency: A Review of the State of the Current Knowledge
Naboush, A., Roman, C. A. J., & Shapira, I. (2017) · Journal of Investigative Medicine · doi:10.1136/jim-2016-000342 · Cited by 47 · see citing works
Antitumor activity of vorinostat-incorporated nanoparticles against human cholangiocarcinoma cells
Kwak, T. W., Kim, D. H., Jeong, Y., & Kang, D. H. (2015) · Journal of Nanobiotechnology · doi:10.1186/s12951-015-0122-4 · Cited by 46 · see citing works
Endoscopically inserted nasobiliary catheters for high dose-rate brachytherapy as part of neoadjuvant therapy for perihilar cholangiocarcinoma
Mukewar, S. S., Gupta, A., Baron, T. H., Gores, G. J., Furutani, K. M., Haddock, M. G., & Hallemeier, C. L. (2015) · Endoscopy · doi:10.1055/s-0034-1392044 · Cited by 46 · see citing works
Self-citation
Mesothelin Expression Is a Prognostic Factor in Cholangiocellular Carcinoma
Nomura, R., Fujii, H., Abe, M., Sugo, H., Ishizaki, Y., Kawasaki, S., & Hino, O. (2013) · International Surgery · doi:10.9738/intsurg-d-13-00001.1 · Cited by 44 · see citing works
Effects of valproic acid in combination with S-1 on advanced pancreatobiliary tract cancers: clinical study phases I/II.
Iwahashi, S., Utsunomiya, T., Imura, S., Morine, Y., Ikemoto, T., Arakawa, Y., Saito, Y., Ishikawa, D., & Shimada, M. (2014) · PubMed · Cited by 41 · see citing works
Does radiotherapy still have a role in unresected biliary tract cancer?
Pollom, E. L., Alagappan, M., Park, L. S., Whittemore, A. S., Koong, A. C., & Chang, D. T. (2016) · Cancer Medicine · doi:10.1002/cam4.975 · Cited by 39 · see citing works
Systematic underreporting of the population-based incidence of pancreatic and biliary tract cancers
Kilander, C., Mattsson, F., Ljung, R., Lagergren, J., & Sadr‐Azodi, O. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.857429 · Cited by 37 · see citing works
Abstract PL04-05: The first reported results of AG-120, a first-in-class, potent inhibitor of the IDH1 mutant protein, in a Phase I study of patients with advanced IDH1-mutant solid tumors, including gliomas
Burris, H. A., Mellinghoff, I. K., Maher, E. A., Wen, P. Y., Beeram, M., Touat, M., Faris, J. E., Azad, N. S., Cloughesy, T. F., Gore, L., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-pl04-05 · Cited by 36 · see citing works
Loss of ARID1A Expression Presents a Novel Pathway of Carcinogenesis in Biliary Carcinomas
Sasaki, M., Nitta, T., Sato, Y., & Nakanuma, Y. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw071 · Cited by 34 · see citing works
PBRM1 loss is a late event during the development of cholangiocarcinoma
Luchini, C., Robertson, S., Hong, S., Felsenstein, M., Anders, R. A., Pea, A., Nottegar, A., Veronese, N., He, J. P., Weiss, M. J., et al. (2017) · Histopathology · doi:10.1111/his.13234 · Cited by 32 · see citing works
Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival
Hammad, A. Y., Berger, N. G., Eastwood, D. C., Tsai, S., Turaga, K. K., Christian, K. K., Johnston, F. M., Pawlik, T. M., & Gamblin, T. C. (2016) · Annals of Surgical Oncology · doi:10.1245/s10434-016-5560-1 · Cited by 32 · see citing works
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
Kats, L. M., Vervoort, S. J., Cole, R., Rogers, A. J., Gregory, G. P., Vidacs, E., Li, J., Nagaraja, R., Yen, K. E., & Johnstone, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.84 · Cited by 30 · see citing works
Histone Deacetylases and their Inhibitors as Potential Therapeutic Drugs for cholangiocarcinoma - Cell Line findings
Sriraksa, R., & Limpaiboon, T. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2503 · Cited by 26 · see citing works
EZH2 elevates the proliferation of human cholangiocarcinoma cells through the downregulation of RUNX3
Tang, B., Du, J., Li, Y., Tang, F., Wang, Z., & He, S. (2014) · Medical Oncology · doi:10.1007/s12032-014-0271-6 · Cited by 25 · see citing works
The efficacy of portal vein embolization prior to right extended hemihepatectomy for hilar cholangiocellular carcinoma: A retrospective cohort study
Hong, Y., Choi, S., Lee, K. H., Park, S. W., Park, Y. N., Choi, J. S., Lee, W. J., Chung, J. B., & Kim, K. S. (2011) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2010.12.010 · Cited by 24 · see citing works
Intensity-modulated radiotherapy following null-margin resection is associated with improved survival in the treatment of intrahepatic cholangiocarcinoma.
Jia, A. Y., Wu, J., Zhao, Y.-T., Li, Y., Wang, Z., Rong, W., Wang, L., Jin, J., Wang, S., Song, Y.-W., et al. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2014.102 · Cited by 19 · see citing works
Harnessing the Immune System as a Therapeutic Tool in Virus-Associated Cancers
Santana-Dávila, R., Bhatia, S., & Chow, L. Q. M. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.4574 · Cited by 17 · see citing works
Sodium Valproate Inhibits the Growth of Human CholangiocarcinomaIn VitroandIn Vivo
Wang, B., Yang, R., Wu, Y., Li, H., Hu, Z., Chen, Y., & Shengquan, Z. (2013) · Gastroenterology Research and Practice · doi:10.1155/2013/374593 · Cited by 17 · see citing works
Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models
Thomas, D., & Majeti, R. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0270 · Cited by 16 · see citing works
The B7-H1/PD-1 pathway in cancers associated with infections and inflammation: opportunities for therapeutic intervention.
Ott, P. A., & Hodi, F. S. (2013) · PubMed · doi:10.3978/j.issn.2304-3865.2012.11.05 · Cited by 10 · see citing works
Detection of Cholangiocarcinoma by Assay of Methylated DNA Markers in Plasma
Yang, J. D., Yab, T. C., Taylor, W. R., Foote, P. H., Ali, H. A., Lavu, S., Simonson, J. A., Burger, K. N., Mahoney, D. W., Slettedahl, S. W., et al. (2017) · Gastroenterology · doi:10.1016/s0016-5085(17)33526-6 · Cited by 8 · see citing works
Self-citation
Another solution that enables ablative radiotherapy for large liver tumors: Percutaneous interstitial high‐dose rate brachytherapy
Patel, S., Ragab, O. M., & Kamrava, M. R. (2016) · Cancer · doi:10.1002/cncr.30128 · Cited by 4 · see citing works
Misleading figures on trends in mortality from hepatocellular carcinoma in europe†
Duberg, A., & Hultcrantz, R. W. (2008) · Hepatology · doi:10.1002/hep.22671 · Cited by 2 · see citing works

Flagged first, then by citations

Sorted by citations

Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0310-z · Cited by 2,411 · see citing works
Self-citation
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study
Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,139 · see citing works
Self-citation
FGF/FGFR signaling in health and disease
Xie, Y., Su, N., Yang, J., Tan, Q., Huang, S., Jin, M., Ni, Z., Zhang, B., Zhang, D., Luo, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00222-7 · Cited by 904 · see citing works
Cholangiocarcinoma
Brindley, P. J., Bachini, M., Ilyas, S. I., Khan, S. A., Loukas, A. C., Sirica, A. E., Teh, B. T., Wongkham, S., & Gores, G. J. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00300-2 · Cited by 860 · see citing works
Self-citation
Cholangiocarcinoma: Epidemiology and risk factors
Khan, S. A., Tavolari, S., & Brandi, G. (2019) · Liver International · doi:10.1111/liv.14095 · Cited by 791 · see citing works
Self-citation
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews. Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 580 · see citing works
Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 613 · see citing works
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marı́n, J. J. G., Bujanda, L., & Bañales, J. M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 606 · see citing works
Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis
Clements, O., Eliahoo, J., Kim, J. U., Taylor-Robinson, S. D., & Khan, S. A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.007 · Cited by 554 · see citing works
Self-citation
Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians
Moris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2022) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21759 · Cited by 457 · see citing works
Inflammation and Liver Cancer: Molecular Mechanisms and Therapeutic Targets
Yang, Y. M., Kim, S., & Seki, E. (2019) · Seminars in Liver Disease · doi:10.1055/s-0038-1676806 · Cited by 453 · see citing works
AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma
Bowlus, C. L., Arrivé, L., Bergquist, A. M., Deneau, M. R., Forman, L., Ilyas, S. I., Lunsford, K. E., Martínez, M., Sapisochín, G., Shroff, R. T., et al. (2022) · Hepatology · doi:10.1002/hep.32771 · Cited by 447 · see citing works
Self-citation
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations
Affo, S., Nair, A., Brundu, F., Ravichandra, A., Bhattacharjee, S., Matsuda, M., Chin, L., Filliol, A., Wen, W., Song, X., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.012 · Cited by 416 · see citing works
Systemic therapies for intrahepatic cholangiocarcinoma
Kelley, R. K., Bridgewater, J. A., Gores, G. J., & Zhu, A. X. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.009 · Cited by 405 · see citing works
Self-citation
Notch signaling pathway in cancer: from mechanistic insights to targeted therapies
Shi, Q., Xue, C., Zeng, Y., Yuan, X., Chu, Q., Jiang, S., Wang, J., Zhang, Y., Zhu, D., & Li, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01828-x · Cited by 428 · see citing works
Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma
Dong, L., Lu, D., Chen, R., Lin, Y., Zhu, H., Zhang, Z., Cai, S., Cui, P., Song, G., Rao, D., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.12.006 · Cited by 400 · see citing works
Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma
Loeuillard, E. J., Yang, J., Buckarma, E. H., Wang, J., Liu, Y., Conboy, C. B., Pavelko, K. D., Li, Y., O’Brien, D. R., Wang, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137110 · Cited by 370 · see citing works
Self-citation
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
Mazzaferro, V., El‐Rayes, B. F., Busset, M. D. D., Cotsoglou, C., Harris, W. P., Damjanov, N., Masi, G., Rimassa, L., Personeni, N., Braiteh, F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0334-0 · Cited by 366 · see citing works
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 362 · see citing works
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Busset, M. D. D., & Sapisochín, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 356 · see citing works
WNT/β-catenin signaling in the development of liver cancers
He, S., & Tang, S. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110851 · Cited by 356 · see citing works
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Izquierdo‐Sánchez, L., Lamarca, Á., Casta, A. L., Buettner, S., Utpatel, K., Klümpen, H., Adeva, J., Vogel, A., Lleò, A., Fabris, L., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.010 · Cited by 354 · see citing works
Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma
Job, S., Rapoud, D., Santos, A. D., Gonzalez, P., Desterke, C., Pascal, G., Elarouci, N., Ayadi, M., Adam, R. A., Azoulay, D., et al. (2019) · Hepatology · doi:10.1002/hep.31092 · Cited by 324 · see citing works
Intrahepatic Cholangiocarcinoma: Continuing Challenges and Translational Advances
Sirica, A. E., Gores, G. J., Groopman, J. D., Selaru, F. M., Strazzabosco, M., Wang, X. W., & Zhu, A. X. (2018) · Hepatology · doi:10.1002/hep.30289 · Cited by 317 · see citing works
Self-citation
Molecular Pathogenesis of Cholangiocarcinoma
Labib, P. L. Z., Goodchild, G., & Pereira, S. P. (2019) · BMC Cancer · doi:10.1186/s12885-019-5391-0 · Cited by 314 · see citing works
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma
Montal, R., Sia, D., Montironi, C., Leow, W. Q., Esteban-Fabró, R., Pinyol, R., Torres‐Martín, M., Bassaganyas, L., Moeini, A., Peix, J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.008 · Cited by 304 · see citing works
N7-Methylguanosine tRNA modification enhances oncogenic mRNA translation and promotes intrahepatic cholangiocarcinoma progression
Dai, Z., Liu, H., Liao, J., Huang, C., Ren, X., Zhu, W., Zhu, S., Peng, B., Li, S., Lai, J., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.003 · Cited by 299 · see citing works
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
Mao, J., Wang, D., Long, J., Xu, Y., Lin, J., Song, Y., Xie, F., Xun, Z., Wang, Y., Wang, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003334 · Cited by 280 · see citing works
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0304 · Cited by 263 · see citing works
The potential role of N7-methylguanosine (m7G) in cancer
Luo, Y., Yao, Y., Wu, P. S., Zi, X., Sun, N., & He, J. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01285-5 · Cited by 257 · see citing works
Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma
Ding, G., Ma, J., Yun, J., Chen, X., Yu, L., Zhang, S., Shi, J.-Y., Chang, Y., Ji, Y., Wang, X., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.030 · Cited by 251 · see citing works
M6A Demethylase ALKBH5 Regulates PD-L1 Expression and Tumor Immunoenvironment in Intrahepatic Cholangiocarcinoma
Qiu, X., Yang, S., Wang, S., Wu, J., Zheng, B. J., Wang, K., Shen, S., Jeong, S., Li, Z., Zhu, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0468 · Cited by 244 · see citing works
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Ilyas, S. I., Affò, S., Goyal, L., Lamarca, Á., Sapisochín, G., Yang, J. D., & Gores, G. J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00770-1 · Cited by 221 · see citing works
Self-citation
Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids
Artegiani, B., van Voorthuijsen, L., Lindeboom, R. G. H., Seinstra, D., Heo, I., Tapia, P., López-Iglesias, C., Postrach, D., Dayton, T., Oka, R., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.017 · Cited by 218 · see citing works
Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review
Boscoe, A. N., Rolland, C., & Kelley, R. K. (2019) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2019.03.10 · Cited by 209 · see citing works
Self-citation
Biliary Tract Cancer at CT: A Radiomics-based Model to Predict Lymph Node Metastasis and Survival Outcomes
Ji, G., Zhang, Y., Zhang, H., Zhu, F.-P., Wang, K., Xia, Y., Zhang, Y., Jiang, W., Li, X., & Wang, X. (2018) · Radiology · doi:10.1148/radiol.2018181408 · Cited by 200 · see citing works
Immunology and immunotherapy of cholangiocarcinoma
Greten, T. F., Schwabe, R. F., Bardeesy, N. M., Ma, L., Goyal, L., Kelley, R. K., & Wang, X. W. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00741-4 · Cited by 193 · see citing works
Self-citation
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187 · see citing works
Cholangiocarcinoma
Sarcognato, S., Sacchi, D., Fassan, M., Fabris, L., Cadamuro, M., Zanus, G., Cataldo, I., Capelli, P., Baciorri, F., Cacciatore, M., et al. (2021) · Pathologica · doi:10.32074/1591-951x-252 · Cited by 187 · see citing works
Biomarkers for Hepatobiliary Cancers
Nault, J., & Villanueva, A. (2020) · Hepatology · doi:10.1002/hep.31175 · Cited by 179 · see citing works
Surgical Treatments of Hepatobiliary Cancers
Gunasekaran, G., Bekki, Y., Lourdusamy, V., & Schwartz, M. (2020) · Hepatology · doi:10.1002/hep.31325 · Cited by 172 · see citing works
Current and emerging therapies for advanced biliary tract cancers
Kam, A. E., Masood, A., & Shroff, R. T. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00171-0 · Cited by 167 · see citing works
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., Cristoferi, L., Ciaccio, A., Cortinovis, D. L., Invernizzi, P., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100737 · Cited by 168 · see citing works
Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development
Huang, X., Tang, T., Zhang, G., & Liang, T. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01342-6 · Cited by 155 · see citing works
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma
Lin, J., Yang, X., Long, J., Zhao, S., Mao, J., Wang, D., Bai, Y., Bian, J., Zhang, L., Yang, X., et al. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-20-338 · Cited by 153 · see citing works
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma
Diggs, L. P., Ruf, B., Ma, C., Heinrich, B., Cui, L., Zhang, Q., McVey, J. C., Wabitsch, S., Heinrich, S., Rosato, U., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.037 · Cited by 151 · see citing works
Self-citation
Pathogenesis of Cholangiocarcinoma
Rodrigues, P. M., Olaizola, P., Paiva, N. A., Olaizola, I., Lizaso, A. A., Landa-Magdalena, A., Bujanda, L., Perugorria, M. J., & Bañales, J. M. (2020) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-030220-020455 · Cited by 143 · see citing works
A radiomics approach to predict lymph node metastasis and clinical outcome of intrahepatic cholangiocarcinoma
Ji, G., Zhu, F., Zhang, Y., Liu, X.-S., Wu, F., Wang, X., Xia, Y., Zhang, Y., Jiang, W., Li, X., et al. (2019) · European Radiology · doi:10.1007/s00330-019-06142-7 · Cited by 141 · see citing works
Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma
Song, F., Hu, B., Cheng, J., Sun, Y., Zhou, K., Wang, P.-X., Guo, W., Zhou, J., Fan, J., Chen, Z., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02749-7 · Cited by 137 · see citing works
Morbidity and mortality after major liver resection in patients with perihilar cholangiocarcinoma: A systematic review and meta-analysis
Franken, L. C., Schreuder, A. M., Roos, E., van Dieren, S., Busch, O. R., Besselink, M. G., & van Gulik, T. M. (2019) · Surgery · doi:10.1016/j.surg.2019.01.010 · Cited by 136 · see citing works
Practical considerations in screening for genetic alterations in cholangiocarcinoma
Bekaii‐Saab, T., Bridgewater, J. A., & Normanno, N. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.012 · Cited by 136 · see citing works
Recent advances of immunotherapy for biliary tract cancer
Rizzo, A., Ricci, A. D., & Brandi, G. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1853527 · Cited by 132 · see citing works
A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma
Sun, W., Patel, A. K., Normolle, D. P., Patel, K., Ohr, J. P., Lee, J. J., Bahary, N., Chu, E., Streeter, N. R., & Drummond, S. (2018) · Cancer · doi:10.1002/cncr.31872 · Cited by 125 · see citing works
Immunobiology of cholangiocarcinoma
Loeuillard, E. J., Conboy, C. B., Gores, G. J., & Ilyas, S. I. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.06.003 · Cited by 123 · see citing works
Self-citation
METTL3 promotes intrahepatic cholangiocarcinoma progression by regulating IFIT2 expression in an m6A-YTHDF2-dependent manner
Xu, Q., Tien, Y.-C., Shi, Y.-H., Chen, S., Zhu, Y., Huang, X., Huang, C., Zhao, W., & Yin, X.-Y. (2022) · Oncogene · doi:10.1038/s41388-022-02185-1 · Cited by 122 · see citing works
Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review
Rizzo, A., & Brandi, G. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100354 · Cited by 118 · see citing works
Non-alcoholic Fatty Liver Disease as a Canonical Example of Metabolic Inflammatory-Based Liver Disease Showing a Sex-Specific Prevalence: Relevance of Estrogen Signaling
Torre, S. D. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.572490 · Cited by 118 · see citing works
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
Feng, K., Liu, Y., Zhao, Y., Yang, Q., Dong, L., Liu, J., Li, X., Zhao, Z., Mei, Q., & Han, W. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000367 · Cited by 114 · see citing works
Evolving role of regorafenib for the treatment of advanced cancers
Grothey, A. F., Blay, J., Pavlakis, N., Yoshino, T., & Bruix, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101993 · Cited by 116 · see citing works
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation
Song, X., Xu, H., Wang, P., Wang, J., Affò, S., Wang, H., Xu, M. M., Liang, B.-Y., Che, L., Qiu, W., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.018 · Cited by 113 · see citing works
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer
Rizzo, A., Ricci, A. D., & Brandi, G. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1897102 · Cited by 111 · see citing works
Circulating Tumor DNA in Biliary Tract Cancer: Current Evidence and Future Perspectives
Rizzo, A., Ricci, A. D., Tavolari, S., & Brandi, G. (2020) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20203 · Cited by 105 · see citing works
A PLCB1–PI3K–AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression
Liang, S., Guo, H., Ma, K., Li, X., Wu, D., Wang, Y., Wang, W., Zhang, S., Cui, Y., Liu, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1538 · Cited by 105 · see citing works
Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis
Lendvai, G., Szekerczés, T., Illyés, I., Dóra, R., Kontsek, E., Gógl, A., Kiss, A., Werling, K., Kovalszky, I., Schaff, Z., et al. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0491-8 · Cited by 104 · see citing works
Therapy of Primary Liver Cancer
Feng, M., Pan, Y., Kong, R., & Shu, S. (2020) · The Innovation · doi:10.1016/j.xinn.2020.100032 · Cited by 102 · see citing works
A hepatocyte-targeting nanoparticle for enhanced hepatobiliary magnetic resonance imaging
Zhang, H., Guo, Y., Jiao, J., Qiu, Y. N., Miao, Y., He, Y., Li, Z., Xia, C., Li, L., Cai, J., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00975-2 · Cited by 102 · see citing works
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
Rushbrook, S., Kendall, T. J., Zen, Y., Albazaz, R., Manoharan, P., Pereira, S. P., Sturgess, R. P., Davidson, B. R., Malik, H., Manas, D., et al. (2023) · Gut · doi:10.1136/gutjnl-2023-330029 · Cited by 100 · see citing works
Self-citation
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives
Rizzo, A., Ricci, A. D., & Brandi, G. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1837774 · Cited by 99 · see citing works
FGFR2 Extracellular Domain In-Frame Deletions Are Therapeutically Targetable Genomic Alterations That Function as Oncogenic Drivers in Cholangiocarcinoma
Cleary, J. M., Raghavan, S., Wu, Q., Li, Y. Y., Spurr, L. F., Gupta, H. V., Rubinson, D. A., Fetter, I. J., Hornick, J. L., Nowak, J. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1669 · Cited by 95 · see citing works
Patients with Cholangiocarcinoma Present Specific RNA Profiles in Serum and Urine Extracellular Vesicles Mirroring the Tumor Expression: Novel Liquid Biopsy Biomarkers for Disease Diagnosis
Lapitz, A., Arbelaiz, A., O’Rourke, C. J., Lavín, J. L., Casta, A. L., Ibarra, C., Jimeno, J. P., Santos‐Laso, Á., Izquierdo‐Sánchez, L., Krawczyk, M. J., et al. (2020) · Cells · doi:10.3390/cells9030721 · Cited by 94 · see citing works
Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT‐ME‐1 trial
von Einem, J. C., Guenther, C., Volk, H., Grütz, G., Hirsch, D. D., Salat, C., Stoetzer, O. J., Nelson, P. J., Michl, M., Modest, D. P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32230 · Cited by 93 · see citing works
Early Diagnosis And Management Of Malignant Distal Biliary Obstruction: A Review On Current Recommendations And Guidelines
Viesca, M. F. Y., & Arvanitakis, M. (2019) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s195714 · Cited by 93 · see citing works
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma
Ma, B., Meng, H., Tian, Y., Wang, Y., Song, T., Zhang, T., Wu, Q., Cui, Y., Li, H., Zhang, W., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06804-6 · Cited by 94 · see citing works
Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Makawita, S., Abou‐Alfa, G. K., Roychowdhury, S., Sadeghi, S., Borbath, I., Goyal, L., Cohn, A. L., Lamarca, Á., Oh, D., Macarulla, T. M., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0299 · Cited by 93 · see citing works
Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma
Cleary, J. M., Rouaisnel, B., Daina, A., Raghavan, S., Roller, L. A., Huffman, B. M., Singh, H., Wen, P. Y., Bardeesy, N. M., Zoete, V., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00304-5 · Cited by 92 · see citing works
Targeting tumour-intrinsic N 7 -methylguanosine tRNA modification inhibits MDSC recruitment and improves anti-PD-1 efficacy
Liu, H., Zeng, X., Ren, X., Zhang, Y., Huang, M., Tan, L., Dai, Z., Lai, J., Xie, W., Chen, Z., et al. (2022) · Gut · doi:10.1136/gutjnl-2022-327230 · Cited by 92 · see citing works
Artificial intelligence in liver cancers: Decoding the impact of machine learning models in clinical diagnosis of primary liver cancers and liver cancer metastases
Bakrania, A. K., Joshi, N., Zhao, X., Zheng, G., & Bhat, M. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106706 · Cited by 96 · see citing works
NEO-GAP: A Single-Arm, Phase II Feasibility Trial of Neoadjuvant Gemcitabine, Cisplatin, and Nab-Paclitaxel for Resectable, High-Risk Intrahepatic Cholangiocarcinoma
Maithel, S. K., Keilson, J. M., Cao, H. S. T., Rupji, M., Mahipal, A., Lin, B. S.-L., Javle, M. M., Cleary, S. P., Akce, M., Switchenko, J. M., et al. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-13809-5 · Cited by 90 · see citing works
New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma
Massironi, S., Pilla, L., Elvevi, A., Longarini, R., Rossi, R. E., Bidoli, P., & Invernizzi, P. (2020) · Cells · doi:10.3390/cells9030688 · Cited by 88 · see citing works
Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer
Rizzo, A., & Brandi, G. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1890031 · Cited by 87 · see citing works
Annexin10 Promotes Extrahepatic Cholangiocarcinoma Metastasis by Facilitating EMT via PLA2G4A/PGE2/STAT3 Pathway
Sun, R., Liu, Z., Qiu, B., Chen, T., Li, Z., Zhang, X., Xu, Y., & Zhang, Z. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.062 · Cited by 84 · see citing works
Resveratrol interrupts the pro-invasive communication between cancer associated fibroblasts and cholangiocarcinoma cells
Thongchot, S., Ferraresi, A., Vidoni, C., Loilome, W., Yongvanit, P., Namwat, N., & Isidoro, C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.031 · Cited by 84 · see citing works
Current Perspectives on Opisthorchiasis Control and Cholangiocarcinoma Detection in Southeast Asia
Khuntikeo, N., Titapun, A., Loilome, W., Yongvanit, P., Thinkhamrop, B., Chamadol, N., Boonmars, T., Nethanomsak, T., Andrews, R. H., Petney, T. N., et al. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00117 · Cited by 83 · see citing works
TWEAK/Fn14 signalling promotes cholangiocarcinoma niche formation and progression
Dwyer, B. J., Jarman, E. J., Gogoi-Tiwari, J., Ferreira-González, S., Boulter, L., Guest, R. V., Kendall, T. J., Kurian, D., Kilpatrick, A. M., Robson, A. J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.11.018 · Cited by 82 · see citing works
Animal models of cholangiocarcinoma
Loeuillard, E. J., Fischbach, S. R., Gores, G. J., & Ilyas, S. I. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.03.026 · Cited by 82 · see citing works
Self-citation
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow
Rizzo, A., Ricci, A. D., Tober, N., Nigro, M. C., Mosca, M., Palloni, A., Abbati, F., Frega, G., Lorenzo, S. D., Tavolari, S., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.14282 · Cited by 80 · see citing works
Diagnosis of cholangiocarcinoma from microscopic hyperspectral pathological dataset by deep convolution neural networks
Li, S., Zhou, M., Li, Q., Hu, M., Wen, Y., Zhang, J., Lu, Y., & Chu, J. (2021) · Methods · doi:10.1016/j.ymeth.2021.04.005 · Cited by 80 · see citing works
Cell of origin in biliary tract cancers and clinical implications
Moeini, A., Haber, P. K., & Sia, D. (2021) · JHEP Reports · doi:10.1016/j.jhepr.2021.100226 · Cited by 80 · see citing works
High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
Ahn, S., Lee, J.-C., Shin, D. W., Kim, J., & Hwang, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-69366-4 · Cited by 78 · see citing works
Recent Advancements in Design, Application, and Simulation Studies of Hybrid Solar Drying Technology
Jha, A., & Tripathy, P. P. (2020) · Food Engineering Reviews · doi:10.1007/s12393-020-09223-2 · Cited by 78 · see citing works
HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium
Xu, Y., Liu, Z., Pan, C., Yang, X., Ning, S., Liu, H., Guo, S., Yu, J., & Zhang, Z. (2018) · Oncogene · doi:10.1038/s41388-018-0485-8 · Cited by 77 · see citing works
Treatment of Intrahepatic Cholangiocarcinoma—A Multidisciplinary Approach
Krenzien, F., Nevermann, N., Krombholz, A., Benzing, C., Haber, P., Fehrenbach, U., Lurje, G., Pelzer, U., Pratschke, J., Schmelzle, M., et al. (2022) · Cancers · doi:10.3390/cancers14020362 · Cited by 76 · see citing works
Role of Cancer Stem Cells in Cholangiocarcinoma and Therapeutic Implications
Wu, H., & Chu, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174154 · Cited by 73 · see citing works
Our emerging understanding of the roles of long non-coding RNAs in normal liver function, disease, and malignancy
Mahpour, A., & Mullen, A. C. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100177 · Cited by 75 · see citing works
Clinical Significance of Preoperative Serum CEA, CA125, and CA19-9 Levels in Predicting the Resectability of Cholangiocarcinoma
Fang, T., Wang, H., Wang, Y., Lin, X., Cui, Y., & Wang, Z. (2019) · Disease Markers · doi:10.1155/2019/6016931 · Cited by 74 · see citing works
PET/CT-based radiomics of mass-forming intrahepatic cholangiocarcinoma improves prediction of pathology data and survival
Fiz, F., Masci, C., Costa, G., Sollini, M., Chiti, A., Ieva, F., Torzilli, G., & Viganò, L. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05765-1 · Cited by 74 · see citing works
The genomic landscape of cholangiocarcinoma reveals the disruption of post-transcriptional modifiers
Zhang, Y., Ma, Z., Li, C., Wang, C., Jiang, W., Chang, J., Han, S., Lu, Z., Shao, Z., Wang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30708-7 · Cited by 74 · see citing works
Inflammation and Progression of Cholangiocarcinoma: Role of Angiogenic and Lymphangiogenic Mechanisms
Roy, S., Glaser, S. S., & Chakraborty, S. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00293 · Cited by 72 · see citing works
BIOMEX: an interactive workflow for (single cell) omics data interpretation and visualization
Taverna, F., Goveia, J., Karakach, T. K., Khan, S., Rohlenová, K., Treps, L., Subramanian, A., Schoonjans, L., Dewerchin, M. A., Eelen, G., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa332 · Cited by 72 · see citing works
Self-citation
WDR5 facilitates EMT and metastasis of CCA by increasing HIF-1α accumulation in Myc-dependent and independent pathways
Chen, T., Li, K., Liu, Z., Liu, J., Wang, Y., Sun, R., Li, Z., Qiu, B., Zhang, X., Ren, G., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.017 · Cited by 72 · see citing works

Cholangiocarcinoma
Lasagni, A., Strazzabosco, M., Guido, M., Fabris, L., & Cadamuro, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-65908-0_14 · Cited by 1 · see citing works
Cancer review: Cholangiocarcinoma
Blechacz, B. R. A., Ghouri, Y. A., & Mian, I. (2015) · Journal of Carcinogenesis · doi:10.4103/1477-3163.151940 · Cited by 154 · see citing works
Clinical treatment of cholangiocarcinoma: an updated comprehensive review
Elvevi, A., Laffusa, A., Scaravaglio, M., Rossi, R. E., Longarini, R., Stagno, A. M., Cristoferi, L., Ciaccio, A., Cortinovis, D. L., Invernizzi, P., et al. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100737 · Cited by 168 · see citing works
Pathogenesis, Diagnosis, and Management of Cholangiocarcinoma
Ilyas, S. I., & Gores, G. J. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.10.013 · Cited by 1,311 · see citing works
Self-citation
Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategies
Lu, X., Xu, S., Deng, Z., Wang, M., & Chen, F. (2025) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaf021 · Cited by 9 · see citing works

Authors: Ilyas, S. I., Khan, S. A., Hallemeier, C. L., Kelley, R. K., & Gores, G. J.
Affiliations: Mayo Clinic (US)
Hammersmith Hospital (GB)
University of California San Francisco Medical Center (US)
Corresponding author: Gores, Gregory J.
ORCID: Ilyas, Sumera I.
Khan, Shahid A.
Hallemeier, Christopher L.
Kelley, Robin K.
Gores, Gregory J.
Venue: Nature Reviews Clinical Oncology
Publisher: Springer Science and Business Media LLC
Published: 2017-10-10
Volume: 15
Issue: 2
Pages: 95-111
ISSN: 1759-4774 (ISSN-L)
1759-4782
DOI: 10.1038/nrclinonc.2017.157
PMC: PMC5819599
OpenAlex: W2763492611
Cited by: 1,626
References: 175
Citations by year: 2026: 88 · 2025: 164 · 2024: 252 · 2023: 247 · 2022: 253 · 2021: 272 · 2020: 209 · 2019: 82 · 2018: 51 · 2017: 1
FWCI: 19.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature Reviews Clinical Oncology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
Funders: Cholangiocarcinoma Foundation
National Institutes of Health
Institute of Chemistry, Chinese Academy of Sciences
National Cancer Institute (R03CA212877)
National Institute of Diabetes and Digestive and Kidney Diseases (R56DK059427, R01DK059427, P30DK084567)
Topics: Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords: cholangiocarcinoma, intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, distal cholangiocarcinoma, pathogenesis, surgical resection, liver transplantation, neoadjuvant chemoradiotherapy, locoregional chemotherapy, external beam radiotherapy, genetic landscape, molecular targets, precision medicine, immunotherapy, tumor stroma, biomarkers
MeSH terms: Adult, Cell Differentiation, Humans, Liver Neoplasms, Prognosis, Liver Transplantation, Cholangiocarcinoma, Neoadjuvant Therapy, Precision Medicine, Molecular Targeted Therapy, Chemoradiotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cholangiocarcinoma — evolving concepts and therapeutic strategies

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks